Valeant Pharmaceuticals International

Valeant Pharmaceuticals International
Name	Valeant Pharmaceuticals International
Type	Public (historical)
Industry	Pharmaceuticals
Founded	1960 (as ICN Pharmaceuticals)
Headquarters	Laval, Quebec; later Bridgewater, New Jersey
Key people	Michael Pearson (businessman), J. Michael Pearson; Howard Schiller; Joseph C. Papa
Products	Pharmaceuticals, dermatology, ophthalmology, neurology, branded generics
Revenue	(peak) 2015

Valeant Pharmaceuticals International was a multinational specialty pharmaceutical and medical device company known for rapid acquisition strategy, aggressive pricing, and major regulatory and legal scrutiny. The company grew through successive takeovers of branded drug portfolios and dermatology firms, provoking attention from investors, legislators, regulators, and media. Its trajectory intersected with high-profile corporate governance debates, activist investors, and landmark hearings in the United States Congress.

History

Valeant's origins trace to ICN Pharmaceuticals founded by Milton I. Shapiro; corporate transformations and rebrandings preceded a growth phase led by management teams including Michael Pearson (businessman) in the 2000s. Strategic acquisitions targeted companies such as Biovail Corporation, Bausch & Lomb (later divested), Salix Pharmaceuticals, Sculptor Capital Management-linked deals, and dermatology firms like Ortho Dermatologics-adjacent assets. The company executed leveraged buyouts and hostile bids, engaging with firms like Allergan during takeover attempts that drew scrutiny from hedge funds including Pershing Square Capital Management and activists such as Bill Ackman. Major events included congressional testimony, regulatory investigations by the United States Securities and Exchange Commission, and legal actions in multiple jurisdictions including Canada and Brazil.

Corporate structure and leadership

Valeant's corporate governance featured a centralized acquisition-led board and executive team including CEOs such as J. Michael Pearson and later Joseph C. Papa. Boards incorporated directors with experience from firms like McKinsey & Company alumni, private equity executives, and former executives from companies such as Pfizer and Merck & Co.. Institutional investors ranged from BlackRock to Vanguard Group and activist stakes from hedge funds including Pershing Square Capital Management. Headquarters shifts involved offices in Laval, Quebec, Bridgewater, New Jersey, and operational centers near pharmaceutical clusters such as Basel and Boston. Corporate financing leveraged relationships with investment banks like Goldman Sachs and JPMorgan Chase to structure debt facilities and bond offerings.

Business operations and products

Valeant operated in therapeutic areas including dermatology, ophthalmology, gastroenterology, and neurology through portfolios acquired from specialty companies such as Bausch & Lomb, Salix Pharmaceuticals, Dermira assets, and dermatology chains akin to Salonpas-style topical portfolios. The company marketed branded pharmaceuticals, over-the-counter treatments, and medical devices, distributing via channels including wholesalers like McKesson Corporation, pharmacy benefit managers such as Express Scripts, and retail chains like Walgreens Boots Alliance. Research and development investments were limited compared to peers such as Johnson & Johnson or GlaxoSmithKline, with emphasis on in-licensing, lifecycle management, and price optimization of existing products acquired from companies like Fujisawa Pharmaceutical-era assets.

Controversies and legal issues

Valeant became synonymous with pricing controversies after notable price increases on acquired drugs, attracting comparisons to cases involving firms like Turing Pharmaceuticals and executives such as Martin Shkreli. Congressional hearings involved lawmakers from committees including the United States House Committee on Oversight and Reform and Senate Finance Committee, while regulatory probes were conducted by the United States Securities and Exchange Commission and authorities in Ontario and Quebec. Class action lawsuits alleged accounting irregularities and disclosure failures brought by plaintiffs represented by law firms experienced in securities litigation with precedents from cases against Enron-era defendants. Antitrust and competition concerns arose in merger reviews before agencies such as the Federal Trade Commission and European regulators including European Commission (European Union) bodies. Criminal investigations touched on allegations in multiple jurisdictions, prompting settlements and fines handled via negotiations with prosecutors in United States Department of Justice-linked processes.

Financial performance and acquisitions

Valeant's growth strategy relied on serial acquisitions financed through high-yield debt, bond issuances underwritten by banks like Citigroup and Bank of America, and share repurchase programs influenced by market makers including Goldman Sachs. Acquisitions such as Salix Pharmaceuticals and others propelled revenue growth into the billions by the mid-2010s, but leverage and investor confidence collapsed following investigative reports from firms such as Citron Research and The New York Times coverage. Stock price volatility led to billionaire investor interventions, margin calls, and restructuring efforts including asset divestitures to firms like Sanofi and Allergan—transactions that required negotiation with creditors and restructuring advisors from firms such as Deloitte and PwC.

Regulatory actions and reforms

Regulatory responses included enhanced scrutiny of pharmaceutical pricing by legislators in the United States Congress, inquiries by health agencies such as the Food and Drug Administration, and antitrust review by the Federal Trade Commission. Reforms debated in the aftermath involved proposals to increase transparency in pricing, strengthen Securities Act disclosure standards, and adjust competition policy—policy arenas where stakeholders included think tanks, patient advocacy groups like PhRMA-reacting organizations, and professional societies from dermatology and ophthalmology. Corporate governance reforms at pharmaceutical firms were influenced by precedents set during Valeant's crisis, with proxy advisory firms such as Institutional Shareholder Services and Glass Lewis updating guidance on takeover defenses, executive compensation, and director accountability.

Category:Pharmaceutical companies